Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Analgesic Efficacy of Magnesium and Ketorolac in Ultrasound Supraclavicular Block

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04554862
Recruitment Status : Recruiting
First Posted : September 18, 2020
Last Update Posted : September 18, 2020
Sponsor:
Information provided by (Responsible Party):
Safaa Gaber Ragab, Fayoum University Hospital

Brief Summary:

Despite many regional anesthetic techniques have been described for anesthesia of the brachial plexus which is responsible for the sensory and motor innervation of entire upper limb, still, supraclavicular block (SCB) is the regional anesthetic technique of choice.

SCB has been described as the spinal anesthesia of the upper limb as it offers dense anesthesia of the brachial plexus for the surgical procedures below the arm from elbow to hand. Although the SCB has a high incidence of complications like pneumothorax, the use of ultrasound-guided block improved the safety for the patient. There are several adjuvants have been added to SCB aiming for prolongation of the duration of peripheral nerve block as fentanyl, alpha 2 adrenergic agonist (Dexmedetomidine, Clonidine), tramadol, ketorolac and Magnesium sulfate.

Magnesium has anti-nociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells. Calcium influx leads to a sequence of central sensitization such as windup phenomenon and long term potentiation which are crucial mechanisms that determine the duration and intensity of post-operative pain. Magnesium prevents central sensitization triggered by peripheral nociceptive stimulation in response to painful stimuli.

Non-Steroidal Anti-Inflammatory drugs (NSAID) inhibit synthesis of prostaglandins from arachnoid acid in phospholipid membranes resulting in decreased afferent nociceptive signals from the site of surgery. There are a lot of studies supported the analgesic effect when NSAIDs are concentrated at a peripheral site compared to the systemic administration therapy. Ketorolac is a parenteral NSAIDs. Studies have shown that ketorolac as an adjuvant to local anesthetics during peripheral nerve block enhanced duration and quality of analgesia.


Condition or disease Intervention/treatment Phase
Postoperative Pain Drug: Magnesium sulfate Drug: Ketorolac Tromethamine Procedure: supraclavicular block Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: The Analgesic Efficacy of Adding Magnesium Sulfate Versus Ketorolac to Bupivacaine in Ultrasound-guided Supraclavicular Brachial Plexus Block (A Prospective- Double-blinded Randomized Controlled Trial)
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: the intervention group (M) magnesium sulfate
a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
Drug: Magnesium sulfate
magnesium sulfate will be added to the block
Other Name: magnesium 10%

Procedure: supraclavicular block
it is done by ultrasound- guided

Active Comparator: the intervention group (K) ketorolac
a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
Drug: Ketorolac Tromethamine
ketorolac will be added to the block
Other Name: ketorolac

Procedure: supraclavicular block
it is done by ultrasound- guided




Primary Outcome Measures :
  1. the cumulative morphine consumption [ Time Frame: At 24 hours postoperative ]
    In milligrams


Secondary Outcome Measures :
  1. numerical rating scale (NRS) of postoperative pain [ Time Frame: at 1 hour in the post-anesthesia care unit (PACU) ]
    the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

  2. numerical rating scale (NRS) of postoperative pain [ Time Frame: at 4 hours postoperative ]
    the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

  3. numerical rating scale (NRS) of postoperative pain [ Time Frame: at 8 hours postoperative ]
    the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

  4. numerical rating scale (NRS) of postoperative pain [ Time Frame: at 12 hours postoperative ]
    the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

  5. numerical rating scale (NRS) of postoperative pain [ Time Frame: at 24 hours postoperative ]
    the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)

  6. incidence of opioid related side-effects [ Time Frame: 5 minutes after supraclavicular block till discharge from PACU ]
    side effects (nausea, vomiting, pruritus, excessive sedation, and respiratory depression)

  7. incidence of adverse effects related to the block [ Time Frame: 5 minutes after supraclavicular block till discharge from PACU ]
    adverse events (e.g. vascular puncture, local anesthetic toxicity, and pneumothorax)

  8. time to the first requirement of analgesic supplement [ Time Frame: 5 minutes After supraclavicular block till first requirement of analgesic ]
    In minutes

  9. Duration of surgical procedures [ Time Frame: 5 minutes after completion of surgical procedures ]
    In minutes

  10. Assessment of heart rate [ Time Frame: from the start of the block till completion of surgical procedures ]
    In beats per minutes

  11. Assessment of mean blood pressure [ Time Frame: from the start of the block till completion of surgical procedures ]
    In millimetre mercury (mmHg)

  12. Assessment of respiratory rate [ Time Frame: from the start of the block till completion of surgical procedures ]
    Number of breaths per minute

  13. Assessment of Oxygen saturation [ Time Frame: from the start of the block till completion of surgical procedures ]
    In percentage through use of pulse oximetry

  14. Age [ Time Frame: 10 minutes before surgery ]
    in years

  15. Weight [ Time Frame: 10 minutes before surgery ]
    in kilograms (kg)

  16. Height [ Time Frame: 10 minutes before surgery ]
    in meters (m)

  17. Body mass index [ Time Frame: 10 minutes before surgery ]
    in kg/m square



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) physical status from I to III participants who were scheduled for surgical procedures of the arm from elbow to hand

Exclusion Criteria:

  • Patient refusal.
  • Contraindication to regional anesthesia (coagulopathy, allergy to the local anesthetic or any adjuvants added, severe thrombocytopenia, pre-existing neuropathy in the operative limb, infection at puncture site).
  • Sepsis.
  • Pregnant or lactating women.
  • Hepatic or renal dysfunction.
  • Any drug or opioid abuse.
  • Surgical procedures for more than 3h.
  • Advanced cardiac diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04554862


Contacts
Layout table for location contacts
Contact: Eman M Ahmed, Bch 01008872472 ext 002 drhouse2007@gmail.com
Contact: Safaa G Ragab, MD 01004631943 ext 002 safaagbr705@gmail.com

Locations
Layout table for location information
Egypt
Fayoum University hospital Recruiting
Madīnat Al Fayyūm, Faiyum Governorate, Egypt, 63514
Contact: Safaa G Ragab, MD    01004631943 ext 002    safaagbr705@gmail.com   
Contact: Yasser S Mostafa, M.Sc.    01010509735 ext 002    ysm03@fayoum.edu.eg   
Sponsors and Collaborators
Fayoum University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Safaa G Ragab, MD Faculty of medicine, Fayoum university
Publications:
Layout table for additonal information
Responsible Party: Safaa Gaber Ragab, Lecturer of anesthesiology, Fayoum University Hospital
ClinicalTrials.gov Identifier: NCT04554862    
Other Study ID Numbers: M419
First Posted: September 18, 2020    Key Record Dates
Last Update Posted: September 18, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Safaa Gaber Ragab, Fayoum University Hospital:
Magnesium
Ketorolac
Supraclavicular block
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Ketorolac
Ketorolac Tromethamine
Magnesium Sulfate
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics
Central Nervous System Depressants
Anti-Arrhythmia Agents
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Tocolytic Agents
Reproductive Control Agents